Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Source:http://linkedlifedata.com/resource/pubmed/id/20139391

Download in:

View as

General Info

PMID
20139391